Gilead Sciences Inc (NASDAQ: GILD) has reported a loss for its first fiscal quarter (ending March 31) of $-3.34 versus $0.81 for the same period a year ago. E.P.S. were $0.40 for the latest four quarters through March 31 versus $4.46 for the same period a year ago.
Recent Price Action
On 4/25/24, Gilead Sciences Inc (NASDAQ: GILD) stock declined by -2.7%, closing at $65.27. Moreover, exceptionally high trading volume at 215% of normal accompanied the decline. Relative to the market the stock has been weak over the last nine months and has declined -2.5% during the last week.
Current PriceTarget Research Rating
GILD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Gilead Sciences has a current Value Trend Rating of D (Negative). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Gilead Sciences has a slightly negative Appreciation Score of 39 and a slightly negative Power Rating of 35, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment